# Resproly

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/resproly

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.resproly.com
- Total disclosed funding: $38M
- Latest round: Series B (May 5, 2022)
- Investors on record: 11

## About

Founded in 2018 and headquartered in Shenzhen, China, Shenzhen Resproly Biopharmaceutical Co., Ltd., trading as Resproly, was established by Yongqi Chen, a former pharmaceutical expert at UK-based Vectura. The company has focused on the development of respiratory system drug delivery technologies and devices. Since its founding, it has received multiple awards in innovation and entrepreneurship competitions across Guangdong Province and nationally, including recognition at the Guangdong Medical Valley Open Day and the “Maker China” innovation contests. In December 2025, Guangzhou Industry Investment Holding Group announced to acquire approximately 1.77 million shares in Resproly at CNY 27.67 apiece for CNY 49 million, in a PIPE transaction.

The company's main products include metered dose inhalation aerosols, inhalation powder aerosols, aerosol inhalers and nasal sprays. Nebulized inhaler is a drug-containing solution, emulsion or suspension placed in a special device, and the contents are released in the form of a mist with the help of a nebulizer system. The company's products are used in asthma, chronic obstructive pulmonary disease (COPD), diabetes, Parkinson's disease and other diseases.

The company generates revenue through the development, manufacturing, and sale of inhalation drugs and associated delivery devices. Revenue also derives from contract production, pharmaceutical sales, and export activities in compliance with regulatory approvals.

## Funding rounds

- Series B, May 5, 2022 — Fuho Capital, Qianhai Ark Capital
- Series B, Feb 1, 2021, $31M — Cowin Capital, CAS Investment Management, YuanBio Venture, Efung Capital, Qianhai Ark Capital, Tianfeng Capital
- Series A, Aug 27, 2019, $7M — Huaige Capital, Yanghe Capital Holding Group Limited, Gree Electric Appliances, Inc of Zhuhai, Shanghai INT Medical Instruments

## Investors

- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A
- Yanghe Capital Holding Group Limited — Series A
- Gree Electric Appliances, Inc of Zhuhai (https://capitalatlas.ai/funds/gree-electric-appliances-inc-of-zhuhai) — Series A
- Shanghai INT Medical Instruments — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B
- Tianfeng Capital (https://capitalatlas.ai/funds/tianfeng-capital) — Series B
- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series B